OncoMatch/Kidney Cancer (RCC)/PD-L1 (CD274)
Kidney Cancer (RCC)PD-L1 (CD274) Clinical Trials
PD-L1 expression is assessed in RCC but is not a strict eligibility criterion for approved checkpoint-based regimens including nivolumab plus ipilimumab, pembrolizumab plus axitinib, or nivolumab plus cabozantinib. PD-L1-high tumors may derive greater benefit in some trials. Active studies explore IO/TKI combination optimization, novel checkpoints (LAG-3, TIGIT), and biomarker strategies to identify patients who can safely omit VEGF-pathway agents.
Top recruiting PD-L1 (CD274) Kidney Cancer (RCC) trials
Ranked by phase and US site count. See all 5 trials matched to your profile →
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
EverImmune
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.